Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Current Research in Physiology and Pharmacology
Review Articles
Submitted: 2023-08-07
Published: 2023-09-30

Aspirin Unveiled: Shielding Hearts from Coronary Artery Disease

Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India.
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India.
Department of Pharmacology, Government Medical College Baramulla, India.
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.
Coronary artery disease Heart Management

Abstract

ABSTRACT

In the realm of cardiovascular protection, aspirin emerges as a potent sentinel against Coronary Artery Disease (CAD). Beyond its well-known pain-relief properties, aspirin's remarkable antiplatelet action takes center stage. By inhibiting platelet aggregation through COX-1 enzyme suppression, aspirin mitigates the formation of arterial thrombi, crucial in averting heart attacks and strokes. Aspirin's role spans both secondary and selective primary prevention. In secondary prevention, it stands as a stalwart defense, substantially lowering the risk of recurrent cardiovascular events. In primary prevention, its application is tailored to high-risk individuals, although careful consideration of bleeding risks is paramount. Yet, aspirin is not immune to scrutiny. Concerns include potential bleeding complications, gastric irritation, and drug interactions. In this evolving landscape, its application aligns with emerging guidelines, fine-tuning its role in CAD management. "Aspirin Unveiled: Shielding Hearts from Coronary Artery Disease" encapsulates aspirin's pivotal stance in cardiovascular protection. As a guardian of platelet activity, it plays a crucial role in curbing CAD's impact, symbolizing hope in the battle for heart health.

Keywords: Coronary artery disease, Heart, Management.

References

  1. P.A.J. C.J.o.t.A.S.o.N. McCullough. Coron Artery Dis. 2007;2(3):611-6.
  2. Maqbool M, Bekele F, Fekadu GJBCT. Therapy, Treatment strategies against triple-
  3. negative breast cancer: an updated review; 2022. p. 15-24.
  4. Libby P, Theroux PJC. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-8. doi: 10.1161/CIRCULATIONAHA.105.537878, PMID 15983262.
  5. Zehravi M, Maqbool M, Ara IJIjoam. Polycystic ovary syndrome and infertility: an update. Int J Adolesc Med Health. 2021;34(2):1-9. doi: 10.1515/ijamh-2021-0073, PMID 34293835.
  6. Fuster V, Badimon L, Badimon JJ. Chesebro, The pathogenesis of coronary artery disease and the acute coronary syndromes, J.H.J.N.E.j.o.m. 1992;326(4):242-50.
  7. Maqbool R, Maqbool M, Zehravi M, Ara IJIjoam. Menstrual distress in females of reproductive age: a literature review. Int J Adolesc Med Health. 2021;34(2):11-7. doi: 10.1515/ijamh-2021-0081, PMID 34293834.
  8. Hertzer NR, Beven EG, Young JR, O’Hara PJ, Ruschhaupt W.F. 3rd, Graor RA et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199(2):223-33. doi: 10.1097/00000658-198402000-00016, PMID 6696538.
  9. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. Int J Adolesc Med Health. 2021;33(6):339-45. doi: 10.1515/ijamh-2021-0058, PMID 34142511.
  10. Shao C, Wang J, Tian J, Tang Y-dJCADT, D. Discovery, coronary artery disease: from mechanism to clinical practice; 2020. p. 1-36.
  11. Ralapanawa U, Sivakanesan RJJoe. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health. 2021;11(2):169-77. doi: 10.2991/jegh.k.201217.001, PMID 33605111.
  12. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. Int J Adolesc Med Health. 2021;33(6):367-73. doi: 10.1515/ijamh-2021-0092, PMID 34420269.
  13. Bauersachs R, Zeymer U, Brière J.B., Marre C, Bowrin K, Huelsebeck MJCt. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054. doi: 10.1155/2019/8295054, PMID 32099582.
  14. Abdar M, Książek W, Acharya UR, Tan R-S, Makarenkov V, Pławiak PJCm. biomedicine, A new machine learning technique for an accurate diagnosis of coronary artery disease. 2019;179:104992.
  15. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M et al. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria Journal of Medicine. 2017;53(2):151-6. doi: 10.1016/j.ajme.2016.05.007.
  16. Barham A, Ibraheem R, S.e.H.J.B.C.D. Zyoud, Cardiac self-efficacy and quality of life in patients with coronary heart disease: a cross-sectional study from Palestine. 2019;19(1):1-12.
  17. Zehravi M, Maqbool M, Ara IJOH. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022;3(1):60-5. doi: 10.1515/openhe-2022-0008.
  18. Zehravi M, Maqbool M, IJIJoAM. Ara, Health, Teenage menstrual dysfunction: an overview. 2022;35(1):15-9.
  19. Higashi Y, Gautam S, Delafontaine P, Sukhanov SJGH, I. Research, IGF-1 and cardiovascular disease. 2019;45:6-16.
  20. Ornish D, Brown SE, Billings J, Scherwitz L, Armstrong WT, Ports TA et al. Can lifestyle changes reverse coronary heart disease?: the Lifestyle Heart Trial. 1990;336(8708):129-33.
  21. Rutledge JC, Hyson DA, Garduno D, Cort DA, Paumer L, CTJJoCR. Kappagoda, Prevention, Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital. 1999;19(4):226-34.
  22. Majeed A, Bashir R, Farooq S, Maqbool MJJoDD. Therapeutics, Preparation, characterization and applications of nanoemulsions: an insight. 2019;9(2):520-7.
  23. Khan S, Cleanthis M, Smout J, Flather M, Stansby GJEJoV, E. Surgery, Lifestyle modification in peripheral arterial disease. 2005;29(1):2-9.
  24. M, Maqbool M, Dar MA, Mushtaq IJJoDD. Mohd. Ther Polycystic Ovary Syndr Mod Epidemic Overview. 2019;9(3):641-4.
  25. Winzer EB, Woitek F, A.J.J.o.t.A.H.A. Linke, Physical activity in the prevention and treatment of coronary artery disease. 2018;7(4):e007725.
  26. Maqbool M, Gani I, M.A.J.A.J.o.P.R. Dar, Development, Antidiabetic effects of some medicinal plants in experimental animals: a review. 2019;7(1):66-9.
  27. Claes J, Buys R, Budts W, Smart N, Cornelissen V.A. Longer-term effects of home-based exercise interventions on exercise capacity and physical activity in coronary artery disease patients: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(3):244-56. doi: 10.1177/2047487316675823, PMID 27798366.
  28. Ara I, Maqbool M. Gani, Pharmacology, Reproductive Health of Women: implications and attributes. I.J.I. Jo.C.R.i.P. 2022:8-18.
  29. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A et al.G.J.A.o.i. medicine, Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. 2003;163(19):2301-5.
  30. Bashir R, Maqbool M, Ara I, Zehravi MJC. An in sight into Novel Drug Delivery System: in situ Gels. 2021;11(1):6.1-7.
  31. Ludvig J, Miner B, Eisenberg M.J. Smoking cessation in patients with coronary artery disease. Am Heart J. 2005;149(4):565-72. doi: 10.1016/j.ahj.2004.09.040, PMID 15990735.
  32. Maqbool M, Fekadu G, Dugassa D, Bekele F, Turi E, Simegnew DJAoN. The pattern of substance abuse in the psychiatry department of a tertiary care of Srinagar hospital, Jammu and Kashmir, India. Arch Neurosci. 2020;7(4). doi: 10.5812/ans.106492.
  33. Ades PA, Savage P.D. Potential benefits of weight loss in coronary heart disease. Prog Cardiovasc Dis. 2014;56(4):448-56. doi: 10.1016/j.pcad.2013.09.009, PMID 24438737.
  34. Fekadu G, Bekele F, Bekele K, Hanbisa S, Belay G, Maqbool MJCT. Drug use evaluation of beta-blockers in medical wards of Nedjo general hospital, Western Ethiopia. Cardiovasc Ther. 2020;2020:2509875. doi: 10.1155/2020/2509875, PMID 32565908.
  35. Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc. 2014;89(10):1368-77. doi: 10.1016/j.mayocp.2014.04.033, PMID 25199859.
  36. Ara I, Zehravi M, Maqbool M, Gani IJJoPR, RSJ-Dd. doi: 10.47363/JPRSR/, A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries, 127 2022.
  37. Michalsen A, Grossman P, Lehmann N, Knoblauch NT, Paul A, Moebus S et al. psychosomatics, Psychological and quality-of-life outcomes from a comprehensive stress reduction and lifestyle program in patients with coronary artery disease: results of a randomized trial. 2005;74(6):344-52.
  38. Maqbool M, Dugassa D, Fekadu GJAoN. Adverse drug reactions of antiepileptic drugs in the neurology department of a tertiary care hospital, Srinagar, Jammu & Kashmir, India. Arch Neurosci. 2021;8(2). doi: 10.5812/ans.112364.
  39. Mathews MJ, Liebenberg L, Mathews EHJNj. The mechanism by which moderate alcohol consumption influences coronary heart disease. Nutr J. 2015;14:33. doi: 10.1186/s12937-015-0011-6, PMID 25889723.
  40. Maqbool M, Zehravi M, Maqbool R, Ara IJC. An overview about treatment of gestational diabetes mellitus: A short communication. 2021;11(3):12.1-5.
  41. Matsumoto C, Miedema MD, Ofman P, Gaziano JM, Sesso H.D. An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. J Cardiopulm Rehabil Prev. 2014;34(3):159-71. doi: 10.1097/HCR.0000000000000042, PMID 24667667.
  42. Zehravi M, Maqbool M, IJIJoAM. Ara, Health, Unfolding the mystery of premenstrual syndrome (PMS): an overview. 2022;35(1):9-13.
  43. Maddox TM, Ho P.M. Ho. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol. 2009;24(5):468-72. doi: 10.1097/HCO.0b013e32832ed62d, PMID 19550308.
  44. Ara I, Maqbool M, Bukhari B, Ara N. Hajam, Technology, Present status, standardization and safety issues with herbal drugs. T J;I.J.o.R.i.P.S:1(3) (2020) 95-101.
  45. Baroletti S, Dell’Orfano HJC. Medication adherence in cardiovascular disease. Circulation. 2010;121(12):1455-8. doi: 10.1161/CIRCULATIONAHA.109.904003, PMID 20351303.
  46. Ara I, Maqbool M. Gani, pharmacology, neuroprotective activity of herbal medicinal products: a review. I.J.I. Jo.C.R.i.P. 2022:1-10.
  47. Mendez CB, Salum NC, Junkes C, Amante LN, C.M.L.J.R.l.-a.d.e. Mendez, Mobile educational follow-up application for patients with peripheral arterial disease. Vol. 27; 2019.
  48. Maqbool M, Rasool S, Dar MA, Bashir R, Khan MJP. Hepatotoxicity and hepatoprotective agents: A Mini review. 2019;7(9):34-40.
  49. Zhou DT, Oektedalen O, Shawarira-Bote S, Stray-Pedersen BJHA-R, Care P. Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study. HIV AIDS (Auckl). 2016;8:165-74. doi: 10.2147/HIV.S113206, PMID 27822124.
  50. Maqbool M, Dar AM, Rasool S, MJJoAPS. Khan, Research, Curious case of drug resistant malaria and artemisinine compounds in the modern era; 2019. p. 1-4.
  51. Maqbool M, Zehravi MJIPM. Neuromodulation, neuroprotective role of polyphenols in treatment of neurological disorders: a review. Vol. 1(1); 2021.
  52. Hankey GJ, Norman PE, Eikelboom JWJJ. Medical treatment of peripheral arterial disease. J.A.M.A. 2006;295(5):547-53. doi: 10.1001/jama.295.5.547, PMID 16449620.
  53. Rayan RA, Zafar I, Rajab H, Zubair MAM, Maqbool M, SJMLAfS et al. Processing, impact of IoT in biomedical applications using machine and deep learning; 2022. p. 339-60.
  54. Ara I, Maqbool M, Fekadu G, Hajam TA. Dar, Research, Pharmaceutical significance of Nigella sativa L., a wonder herb. M J.J.o.A.P.S. 2020;3(4):04-13.
  55. B.D.S.G.J.N.E.J.o. Medicine, A randomized trial of therapies for type 2 diabetes and coronary artery disease. 2009;360(24):2503-15.
  56. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. Int J Adolesc Med Health. 2021;33(6):357-66. doi: 10.1515/ijamh-2021-0084, PMID 34420267.
  57. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch J.H..J.T.A.j.o.c. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819-22. doi: 10.1016/s0002-9149(00)01519-8, PMID 11274933.
  58. Maqbool M, Zehravi M, Maqbool R, Ara IJC. Study of adverse drug reactions in pulmonary medicine department of a tertiary care hospital, Srinagar, Jammu and Kashmir, India. 2021;11(2):8.1-5.
  59. Tran H, Anand SSJJ. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. J.A.M.A. 2004;292(15):1867-74. doi: 10.1001/jama.292.15.1867, PMID 15494585.
  60. Zehravi M, Maqbool R, Maqbool M, IJJoPRI. Ara, to identify patterns of drug usage among patients who seek care in psychiatry outpatient department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. 2021;33(31A):135-40.
  61. Clappers N, Brouwer M.A., Verheugt F.W. Antiplatelet treatment for coronary heart disease. Heart. 2007;93(2):258-65. doi: 10.1136/hrt.2005.071209, PMID 17228079.
  62. M.J.J.o.A.P.S. Maqbool, Research, Evaluation of drug utilization pattern in the pediatric department of a Tertiary Care Hospital in Srinagar, Jammu & Kashmir, India, 2019 6-9.
  63. Rauch U, Osende J.I., Chesebro J.H., Fuster V, Vorchheimer D.A., Harris K et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis. 2000;153(1):181-9. doi: 10.1016/s0021-9150(00)00397-x, PMID 11058714.
  64. Mihos CG, Pineda AM, Santana OJPr. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res. 2014;88:12-9. doi: 10.1016/j.phrs.2014.02.009, PMID 24631782.
  65. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis CJIjoc. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol. 2007;115(2):144-50. doi: 10.1016/j.ijcard.2006.03.094, PMID 17175040.
  66. Maqbool M, Gani IJJoPP, Medicine C. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. JPPCM. 2018;4(4):193-6. doi: 10.5530/jppcm.2018.4.46.
  67. Paravastu S, Mendonca D, Da Silva AJEjov. surgery, beta blockers for peripheral arterial disease. 2009;38(1):66-70.
  68. Ara I, Maqbool M. Gani, Pharmacology, Specificity and Personalized medicine: a novel approach to Cancer management. I.J.I. Jo.C.R.i.P. 2022:11-20.
  69. Chonchol M, Benderly M, Goldbourt UJNDT. Beta-blockers for coronary heart disease in chronic kidney disease. Nephrol Dial Transplant. 2008;23(7):2274-9. doi: 10.1093/ndt/gfm950, PMID 18187497.
  70. Leong DP, McMurray JJ, Joseph PG, S.J.J.o.t.A.C.o.C. Yusuf, From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure. part 2/5, 74(5); 2019. p. 683-98.
  71. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CIJDc. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261-6. doi: 10.2337/diacare.28.9.2261, PMID 16123505.
  72. Dar MA, Maqbool M, Gani I. Ara, Pharmacology, menstruation hygiene and related issues in adolescent girls: A brief commentary. I.J.I. Jo.C.R.i.P. 2023:1-5.
  73. Hoang V, Alam M, Addison D, Macedo F, Virani S, Birnbaum YJCd. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin era: a meta-analysis of randomized-controlled trials. Cardiovasc Drugs Ther. 2016;30(2):189-98. doi: 10.1007/s10557-016-6652-7, PMID 26861251.
  74. Maqbool M, Khan MJP. Hypertension and Pregnancy: an important issue. 2019;7(8):71-8.
  75. GORLIN R, BRACHFELD N, MACLEOD C, BOPP PJC. Effect of nitroglycerin on the coronary circulation in patients with coronary artery disease or increased left ventricular work. Circulation. 1959;19(5):705-18. doi: 10.1161/01.cir.19.5.705, PMID 13652363.
  76. Ara I, Maqbool M, Zehravi M, IJAJCB. Gani, herbs boosting immunity in Covid-19: an overview. 2020;3(3):289-94.
  77. Sawan ZH, Soliman HM, Mostafa AEA. T.E.J.o.H.M. Kamel, A review on nitroglycerin: Present and future. R J. 2023;91(1):4972-4.
  78. Zehravi M, Maqbool M, IJTIJoN. Ara, Dietetics, An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India; 2021. p. 408-18.
  79. Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399-407. doi: 10.1093/eurheartj/ehy811, PMID 30590529.
  80. Maqbool M, Ara I. Gani, pharmacology, the story of polycystic ovarian syndrome: A challenging disorder with numerous consequences for females of reproductive age. I.J.I. Jo.C.R.i.P. 2022:19-31.
  81. Bashir R, Maqbool M, Zehravi M, I.J.A.J.C.S.B. Ara, Utilization of herbal cosmetics: A brief overview. 2021;3:277-88.
  82. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty SJJocp. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23. doi: 10.1002/jcp.28350, PMID 30790284.
  83. Zehravi M, Maqbool M, Ara IJAJoC, Section B. Curcumin–A promising phytocompound of immense potential. 2021;3:271.
  84. Jia S, Liu Y, JJCADT, Yuan D. Discovery, Evidence in guidelines for treatment of coronary artery disease; 2020. p. 37-73.
  85. Dar MA, Maqbool M, Ara IJJoEoM, D. Sciences, metformin and other sulfonylureas for glycemic control in Type 2 diabetic patients at a Tertiary Care Hospital in Jammu & Kashmir; 2023. p. 197-201.
  86. Chen N, Chen L, Jiang S, Wang Z, Liu TJE, Medicine T. Predictive value of P selectin and endothelin-1 for vascular restenosis after interventional procedures for peripheral artery disease. Exp Ther Med. 2019;17(5):3907-12. doi: 10.3892/etm.2019.7407, PMID 30988775.
  87. Dar MA, Maqbool M, Ara IJJoEoM, D. Sciences, patterns of drug use in geriatric patients at a Tertiary Care Teaching Hospital in Jammu And . Kashmir; 2023. p. 182-6.
  88. Loffroy R, Falvo N, Galland C, Fréchier L, Ledan F, Midulla M et al. Intravascular ultrasound in the endovascular treatment of patients with peripheral arterial disease: current role and future perspectives. Front Cardiovasc Med. 2020;7:551861. doi: 10.3389/fcvm.2020.551861, PMID 33344512.
  89. Dar MA, Maqbool M, Ara IJJoEoM, D. Sciences, prescription pattern of antibiotics in pulmonary ward of a tertiary. Jammu and Kashmir: Care Hospital; 2023. p. 171-5.
  90. Arramraju S.K., Janapati R.K., Sanjeeva Kumar E., Mandala G.R. National interventional council data for the year 2018-India. Indian Heart J. 2020;72(5):351-5. doi: 10.1016/j.ihj.2020.07.018, PMID 33189193.
  91. Willie MM, MJASRP. Maqbool, Access to public health services in South Africa’s rural Eastern Cape Province. 2023;1(2):35-54.
  92. Darmoch F, Alraies MC, Al‐Khadra Y, Moussa Pacha H, Pinto DS, EAJ.J.o.t.A.H.A. Osborn, Intravascular ultrasound imaging–guided versus coronary angiography–guided percutaneous coronary intervention: a systematic review and meta-analysis. 2020;9(5):e013678.
  93. Mumtaz S, Behram F, Jadoon DK, Maqbool M, Shah SAA, Khawaja UFJN. Pattern of drug use in the dermatology department of a hospital for common skin conditions. 2022;20(16):2804.
  94. Maqbool M, Nasir N. S.J.I.A.J.O.P.S. Mustafa, Polycystic in ovarian syndrome and its various treatment strategies. 2018;5(9):8470-8.
  95. Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2021;42(27):2657-64. doi: 10.1093/eurheartj/ehab273, PMID 34023903.
  96. Li F, Shi G.W., Yu X.L., Song R.X., Xiao J.Q., Huang H.M. et al. Safety and efficacy of coronary angiography and percutaneous coronary intervention via distal transradial artery access in the anatomical snuffbox: a single-centre prospective cohort study using a propensity score method. BMC Cardiovasc Disord. 2022;22(1):74. doi: 10.1186/s12872-022-02518-8, PMID 35236288.
  97. Maqbool M, Naeem A, S.J.I.A.J.o.P.S. Aamer, diabetes mellitus and its various management strategies. Pract. 2018;5(8):8163-+.
  98. Aoki J, Tanabe KJCI. Mechanisms of drug-eluting stent restenosis. Cardiovasc Interv Ther. 2021;36(1):23-9. doi: 10.1007/s12928-020-00734-7, PMID 33222019.
  99. Maqbool M, Tariq S, S.J.I.A.J.o.P.S. Amjad, Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. 2018;5(8):8070-6.
  100. Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R et al. therapeutics, Drug-eluting stent thrombosis: current and future perspectives. 2021;36:158-68.
  101. Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M et al. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2021;42(27):2643-54. doi: 10.1093/eurheartj/ehab280, PMID 34002202.
  102. Maqbool M, Javed S, AAJ.I.A.J.O.P.S. Bajwa, Assessment OF pain management IN postoperative cases using different scales and questionnaires. 2019;6(1):983-7.
  103. Jinnouchi H, Torii S, Sakamoto A, Kolodgie FD, Virmani R, Finn A.V. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat Rev Cardiol. 2019;16(5):286-304. doi: 10.1038/s41569-018-0124-7, PMID 30546115.
  104. Baek S.W., Kim D.S., Song DH, Kim HB, Lee S, Kim JH et al. Reduced restenosis and enhanced re-endothelialization of functional biodegradable vascular scaffolds by everolimus and magnesium hydroxide. Biomater Res. 2022;26(1):86. doi: 10.1186/s40824-022-00334-x, PMID 36544178.
  105. Maqbool M, Shabbir W. S.J.I.A.J.O.P.S. Aamir, Adverse events of blood transfusion and blood safety in clinical practice. 2018;5(8):8254-9.
  106. Chaus A, Uretsky BFJCD. Bioresorbable vascular scaffolds: a dissolving dream?. Cardiovasc Drugs Ther. 2023;37(1):1-3. doi: 10.1007/s10557-022-07401-4, PMID 36374359.
  107. Maqbool M, Ikram U. A.J.I.A.J.O.P.S. Anwar, Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. 2018;5(8):8060-5.
  108. Sharma SK, Tomey MI, Teirstein PS, Kini AS, Reitman AB, Lee AC et al. North American expert review of rotational atherectomy. Circ Cardiovasc Interv. 2019;12(5):e007448. doi: 10.1161/CIRCINTERVENTIONS.118.007448, PMID 31084239.
  109. Bouisset F, Barbato E, Reczuch K, Dobrzycki S, Meyer-Gessner M, Bressollette E et al., M.J.E.J.o.E.i.C.w.t.W.G.o.I.C.o.t.E.S.o.C. Clinical outcomes of PCI with rotational atherectomy: the European multicentre Euro4C registry. EuroIntervention. 2020;16(4):e305-12. doi: 10.4244/EIJ-D-19-01129, PMID 32250249.
  110. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B et al. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2019;18(4):260-71. doi: 10.1177/1474515119826510, PMID 30667278.
  111. Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A et al. Stranges, Mediterranean‐style diet for the primary and secondary prevention of cardiovascular disease, (3); 2019.
  112. Zyryanov SK, Fitilev SB, Vozzhaev AV, Shkrebniova II, Shindryaeva NN, Klyuev DA et al. Voronko, Medication adherence in patients with stable coronary artery disease in primary care. 2020;6(2):97-103.
  113. Wadden TA, Tronieri JS, Butryn MLJAp. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235-51. doi: 10.1037/amp0000517, PMID 32052997.
  114. Bhatti GK, Reddy AP, Reddy PH, JSJFian. Bhatti, Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease. 2020;11:369.
  115. Jepma P, Jorstad HT, Snaterse M, Ter Riet G, Kragten H, Lachman S et al. Lifestyle modification in older versus younger patients with coronary artery disease. Heart. 2020;106(14):1066-72. doi: 10.1136/heartjnl-2019-316056, PMID 32179587.
  116. Piché M.E., Poirier P, Marette A, Mathieu P, Lévesque V, Bibeau K et al. Benefits of 1-year lifestyle modification program on exercise capacity and diastolic function among coronary artery disease men with and without type 2 diabetes. Metab Syndr Relat Disord. 2019;17(3):149-59. doi: 10.1089/met.2018.0092, PMID 30789304.
  117. Ge C, Ma J, Xu Y, Shi Y.J., Zhao C.H., Gao L et al. Predictors of adherence to home-based cardiac rehabilitation program among coronary artery disease outpatients in China. J Geriatr Cardiol. 2019;16(10):749-55. doi: 10.11909/j.issn.1671-5411.2019.10.003, PMID 31700514.
  118. Hong PC, Chen KJ, Chang YC, Cheng SM, HHJJoNS. Chiang, Effectiveness of theory‐based health information technology interventions on coronary artery disease self‐management behavior: a clinical randomized waitlist‐controlled trial. 2021;53(4):418-27.
  119. Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020;141(19):e779-806. doi: 10.1161/CIR.0000000000000766, PMID 32279539.
  120. Turner BJ, Hollenbeak CS, Weiner M, Ten Have T, Tang S.S. Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008;148(8):578-86. doi: 10.7326/0003-4819-148-8-200804150-00002, PMID 18413619.
  121. Newland PK, Lorenz R, Budhathoki C, Jensen MPJCnr. The presence of symptoms with comorbid conditions in individuals with multiple sclerosis (MS). Clin Nurs Res. 2016;25(5):532-48. doi: 10.1177/1054773815592817, PMID 26122788.
  122. Ferrari R, Abergel H, Ford I, Fox KM, Greenlaw N, Steg PG et al.J.I.j.o. cardiology, Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. 2013;167(6):2938-43.

How to Cite

Bashir Malik, A., Ahmad Mir, M., Qadrie, Z., & Altaf Dar, M. (2023). Aspirin Unveiled: Shielding Hearts from Coronary Artery Disease. International Journal of Current Research in Physiology and Pharmacology, 50–60. Retrieved from https://ijcrpp.com/index.php/ijcrpp/article/view/84